Sumain Faisal

Viking Obesity Pill Faces Steep Climb Against Lilly’s Tirzepatide, Analyst Calls Downtrend Reaction ‘Extreme’

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock’s sell-off is excessive. Latest Ratings for VKTX Date Firm Action From To Feb 2022 Raymond James Maintains Outperform Jul 2021 Raymond James Maintains Outperform May 2021 Raymond James Downgrades Strong Buy Outperform View More Analyst Ratings…

Read More